Compare Stocks → Urgent Nvidia Warning (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANNXNASDAQ:AVDLNASDAQ:NVCT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.88+4.7%$5.63$1.57▼$8.40$444.76M1.291.53 million shs2.88 million shsAVDLAvadel Pharmaceuticals$18.82+2.8%$16.41$9.50▼$19.09$1.70B1.611.00 million shs874,897 shsNVCTNuvectis Pharma$8.14+20.4%$8.32$5.92▼$18.65$149.53M0.4564,859 shs110,794 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+4.72%+3.83%-24.34%+21.09%-3.75%AVDLAvadel Pharmaceuticals+2.84%+5.67%+15.53%+28.11%+32.54%NVCTNuvectis Pharma+20.41%+25.23%-1.33%+15.46%-43.20%Automatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon3.5665 of 5 stars4.53.00.00.02.62.50.6AVDLAvadel Pharmaceuticals2.9702 of 5 stars4.51.00.00.03.11.70.6NVCTNuvectis Pharma1.7379 of 5 stars3.51.00.00.00.65.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon3.00Buy$14.43195.67% UpsideAVDLAvadel Pharmaceuticals3.00Buy$23.6725.75% UpsideNVCTNuvectis Pharma3.00Buy$21.00157.99% UpsideCurrent Analyst RatingsLatest AVDL, NVCT, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024ANNXAnnexonCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/11/2024ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/3/2024ANNXAnnexonCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/1/2024ANNXAnnexonJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $13.003/28/2024ANNXAnnexonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/27/2024ANNXAnnexonWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $12.003/27/2024ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/27/2024ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AAVDLAvadel Pharmaceuticals$27.96M60.97N/AN/A$0.98 per share19.20NVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.78N/AN/AN/AN/A-66.54%-53.52%5/13/2024 (Estimated)AVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A22.14N/AN/A-198.06%-84.51%5/8/2024 (Confirmed)NVCTNuvectis Pharma-$22.26M-$1.43N/AN/AN/AN/A-144.80%-107.80%5/8/2024 (Estimated)Latest AVDL, NVCT, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AAVDLAvadel Pharmaceuticals-$0.25N/A+$0.25N/AN/AN/A 3/26/2024Q4 2023ANNXAnnexon-$0.45-$0.36+$0.09-$0.36N/AN/A3/5/2024Q4 2023NVCTNuvectis Pharma-$0.40-$0.41-$0.01-$0.41N/AN/A3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A14.7214.72AVDLAvadel PharmaceuticalsN/A3.643.36NVCTNuvectis PharmaN/A2.752.75OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AAVDLAvadel Pharmaceuticals69.19%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipANNXAnnexon19.11%AVDLAvadel Pharmaceuticals4.00%NVCTNuvectis Pharma38.85%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon7191.14 million73.72 millionOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableNVCTNuvectis Pharma1318.37 million11.23 millionNot OptionableAVDL, NVCT, and ANNX HeadlinesSourceHeadlineIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - April 17 at 10:02 AMNuvectis Pharma, Inc. to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright Forecasts (NASDAQ:NVCT)marketbeat.com - April 11 at 7:26 AMAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)markets.businessinsider.com - April 8 at 6:43 PMNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Linesfinanznachrichten.de - April 8 at 1:42 PMNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Factsmarkets.businessinsider.com - April 8 at 1:42 PMNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Linesfinance.yahoo.com - April 8 at 8:41 AMNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Linesglobenewswire.com - April 8 at 8:30 AM5 Healthcare Stocks to Buy for 2024investorplace.com - April 2 at 4:30 PMInsider Buys Additional US$51k In Nuvectis Pharma Stockfinance.yahoo.com - March 21 at 6:37 AMInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 5,000 Shares of Stockinsidertrades.com - March 20 at 7:19 AMNuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meetingglobenewswire.com - March 19 at 8:00 AMNuvectis reports initial data from Phase Ib ovarian cancer trialmsn.com - March 15 at 9:38 PMNuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer Treatmentmarketwatch.com - March 15 at 9:48 AMNuvectis Pharma to Present at the 36th Annual Roth Conferenceglobenewswire.com - March 15 at 8:00 AMNuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancerglobenewswire.com - March 14 at 9:00 AMNVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023investorplace.com - March 6 at 1:36 AMNuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progressfinance.yahoo.com - March 5 at 10:11 AMNuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownershipfinance.yahoo.com - February 19 at 12:09 PMNuvectis Pharma Inc NVCTmorningstar.com - February 9 at 11:49 PMCorrection: Nuvectis Pharma Announces Participation at Upcoming Investor Conferencesfinance.yahoo.com - February 9 at 8:47 AMNuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 12:55 PMNuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinomafinance.yahoo.com - December 18 at 8:13 AMNuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdingsfinance.yahoo.com - November 25 at 11:11 AMNuvectis Pharma GAAP EPS of -$0.37msn.com - November 8 at 2:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnnexonNASDAQ:ANNXAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Avadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Nuvectis PharmaNASDAQ:NVCTNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
